C12N 2501/04
Immunosuppressors
Official title: Immunosuppressors, e.g. cyclosporin, tacrolimus
C12N2501/04 (Immunosuppressors) appears on 140 US grants and 211 published applications in this corpus.
Search patents in C12N- Granted patents
- 140
- Published applications
- 211
- Assignees
- 85
- Inventors
- 265
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 2 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 4 |
| 2011 | 1 | 4 |
| 2012 | 1 | 1 |
| 2013 | 1 | 8 |
| 2014 | 1 | 4 |
| 2015 | 3 | 10 |
| 2016 | 2 | 8 |
| 2017 | 6 | 8 |
| 2018 | 4 | 13 |
| 2019 | 9 | 17 |
| 2020 | 10 | 15 |
| 2021 | 30 | 38 |
| 2022 | 25 | 32 |
| 2023 | 9 | 16 |
| 2024 | 13 | 6 |
| 2025 | 6 | 13 |
| 2026 | 14 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods for production of platelets from pluripotent stem cells and compositions thereof4 Aug 2026US RE50,977 E1Astellas Institute for Regenerative Medicine
- Optimized method for expansion and large-scale production of regulatory t cells (Tregs)21 Jul 2026US 12,686,851 B2Central South University
- Methods for production of platelets from pluripotent stem cells and compositions thereof16 Jun 2026US 12,653,840 B2Astellas Institute for Regenerative Medicine
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy16 Jun 2026US 12,655,389 B2Iovance Biotherapeutics, Inc.
- Methods for production of platelets from pluripotent stem cells and compositions thereof16 Jun 2026US RE50,916 E1Astellas Institute for Regenerative Medicine
- Compositions, systems and methods for programming immune cell function through targeted gene regulation1 Oct 2026US 2026/0297545 A1Duke University
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275285 A1Iovance Biotherapeutics, Inc.
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275286 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy55US 10,130,659 B2Iovance Biotherapeutics, Inc. · 2018
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy52US 10,363,273 B2Iovance Biotherapeutics, Inc. · 2019
- Restimulation of cryopreserved tumor infiltrating lymphocytes40US 10,517,894 B2Iovance Biotherapeutics, Inc. · 2019
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy40US 10,537,595 B2Iovance Biotherapeutics, Inc. · 2020
- Restimulation of cryopreserved tumor infiltrating lymphocytes40US 11,026,974 B2Iovance Biotherapeutics, Inc. · 2021